Briefly, patients with severe symptomatic aortic stenosis, who had an estimated 30-day mortality of $15% and a combined mortality and morbidity of <50%, were enrolled in this trial.
It is helpful to look at some key issues and differences that are highlighted by this landmark trial.
1. All-cause mortality: At 1 year, all-cause mortality was lower in the TAVR arm compared with SAVR (14.2% vs. 19.1%; p < 0.001 for noninferiority, p ¼ 0.04 for superiority) (8). At 2 years, mortality was still lower with TAVR (22.2% vs. 28.6%; p ¼ 0.04) (9). At 3 years, the difference is no longer statistically significant (32.9% vs. 39.1%; p ¼ 0.07) (7) . The initial superiority finding had been exciting yet surprising, and although numerous mechanisms had been suggested, none were felt to be entirely convincing (10). Even as we await longer-term results, the current 3-year results suggest that the finding may have been due to chance.
Further, although landmark analyses are not provided, the curves and event rates appear to be fairly parallel after the 3-to 4-month mark. Nonetheless, even the finding that the 2 procedures are similar for mortality to 3 years is a big win for the field itself.
2. Stroke: At 1 year, stroke rates for TAVR versus SAVR were 8.8% versus 12.6% (p ¼ 0.10) (7); at 2 years, rates were 10.9% versus 16.6% (p ¼ 0.05) (8). Now, at 3 years, stroke rates are further lower in the TAVR arm (12.6% vs. 19.0%; p ¼ 0.03). The curves continue to diverge over the 3-year follow-up period (7) . In the PARTNER trial, comparable 3-year stroke rates for balloon-expandable TAVR versus SAVR were 8.2% versus 9.3% (p ¼ 0.76) (11). Although not directly comparable across trials, these are impressive differences (w6.4% absolute difference between CoreValve TAVR and SAVR and w10% absolute difference between the surgical arms of the 2 trials), and the reasons for the same will need to be clearly delineated in the future.
New permanent pacemaker implantation:
Because this is felt to be due to a direct effect of the prosthesis on the conduction system, one would expect the rates to be highest in the periprocedural period. Indeed, the rates of permanent pacemaker implantation were highest within 30 days for TAVR compared with SAVR (19.8% vs. 7.1%; p < 0.001), and 
then stayed high at 1 year (22.3% vs. 11.3%; p < 0.001), 2 years (25.8% vs. 12.8%; p < 0.001), and now 3 years (28.0% vs. 14.5%; p < 0.001). Taking into account that w22% of the study population was enrolled with an existing permanent pacemaker, these data suggest (14, 15) . This will be particularly important for lowerrisk populations, where the risk of mortality from competing hazards will be significantly lower than noted in the current (CoreValve) and PARTNER trials.
Moderate to severe aortic regurgitation was mostly paravalvular in nature in the TAVR arm, and it remained at 5% to 8% from discharge through 3 years.
At first glance, this suggests that paravalvular regurgitation rates were stable over time. 
